<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="643">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705844</url>
  </required_header>
  <id_info>
    <org_study_id>A21-070</org_study_id>
    <nct_id>NCT04705844</nct_id>
  </id_info>
  <brief_title>Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19</brief_title>
  <official_title>Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Adalimumab (Humira) or Placebo in Patients With Mild-Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ology Bioservices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharm-Olam, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chemical, Biological, Radiological, and Nuclear Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ology Bioservices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical study of Humira (adalimumab) or placebo in subjects with mild-moderate COVID-19&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to receive a single dose of adalimumab or placebo. Subjects will receive standard care of therapy (per study site written policies or guidelines) together with adalimumab or matching placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomized, Double-Blind, Placebo-Controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Establish whether treatment with adalimumab is associated with a lower rate of progression to severe disease as defined by severe illness or critical illness, or death in outpatient subjects with COVID-19</measure>
    <time_frame>28 Days</time_frame>
    <description>Proportion of subjects with the following outcomes attributed to COVID-19 from time of first dose through Day 28 following randomization:&#xD;
Death&#xD;
Alive and hospitalized or requiring supplemental oxygen for ≥1 hour&#xD;
Alive and not hospitalized or requiring supplemental oxygen for ≥1 hour</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the safety of adalimumab in subjects with COVID-19</measure>
    <time_frame>28 Days</time_frame>
    <description>Incidence of Grade 3 and Grade 4 clinical adverse events (AEs) from first dose through Day 28 following randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the impact of treatment with adalimumab on clinical course of COVID-19 infection</measure>
    <time_frame>120 Days</time_frame>
    <description>Clinical status by 9-point WHO COVID 19 ordinal scale from first dose through Day 120 following randomization&#xD;
Incidence of venous thromboembolism, CVA, myocardial infarction, and acute kidney injury C from first dose through Day 120 following randomization&#xD;
Time to resolution of symptoms using 14 point COVID-19 Symptom Score from first dose through Day 120 following randomization&#xD;
COVID-19 Clinical Assessment from first dose through Day 120 following randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1444</enrollment>
  <condition>Mild to Moderate COVID-19</condition>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of adalimumab(160 mg administered as 4×40 mg subcutaneous [SC] injections at separate sites on the thigh or abdomen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose of placebo (administered as 4×40 mg subcutaneous [SC] injections at separate sites on the thigh or abdomen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>adalimumab (160 mg administered as 4×40 mg subcutaneous [SC] injections at separate sites on the thigh or abdomen)</description>
    <arm_group_label>Adalimumab</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject (or their legally authorized representative) is willing and able to provide&#xD;
             written informed consent prior to performing study procedures.&#xD;
&#xD;
          -  Understands and agrees to comply with planned study procedures.&#xD;
&#xD;
          -  Male or non-pregnant female adult ≥60 and ≤ 80years of age OR male or non-pregnant&#xD;
             female adult ≥40 and ≤80 years, with one or more of the following risk factors&#xD;
             (asthma, diabetes, hypertension, obesity [body mass index &gt;30], cardiovascular&#xD;
             disease).&#xD;
&#xD;
          -  Has a laboratory-confirmed SARS-CoV-2 infection as determined by FDA-approved rapid&#xD;
             diagnostic (e.g., polymerase chain reaction [PCR]) assay within the preceding 7 days&#xD;
             (168 hours).&#xD;
&#xD;
          -  Has at least 2 COVID-19 related symptoms on the 14-question COVID-19 questionnaire.&#xD;
&#xD;
          -  Has peripheral capillary oxygen saturation (SpO2) &gt;93% by pulse oximetry.&#xD;
&#xD;
          -  C-reactive protein (CRP) &gt;50 mg/L or lymphopenia (&lt;1.5×109/L) or neutrophilia&#xD;
             (&gt;7.5×109/L).&#xD;
&#xD;
          -  Agrees to the collection of blood and urine samples, nasal swabs , and non-invasive&#xD;
             oxygen monitoring (via pulse oximeter) per protocol.&#xD;
&#xD;
          -  Willing to receive 4 injections at separate sites on the thigh or abdomen.&#xD;
&#xD;
          -  Women of childbearing potential must agree to either abstinence or use of at least one&#xD;
             primary form of contraception (not including hormonal contraception) from the time of&#xD;
             screening through Day 29 following randomization.&#xD;
&#xD;
          -  Agrees to not participate in any other clinical trial (both pharmacologic and other&#xD;
             types of interventions) through Day 29 following randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received or contemplating any COVID-19 vaccine or participated in a COVID-19 vaccine&#xD;
             trial.&#xD;
&#xD;
          -  Subject is considered to be in their last few weeks of life prior to this acute&#xD;
             illness.&#xD;
&#xD;
          -  History of pulmonary alveolar proteinosis.&#xD;
&#xD;
          -  History of hematopoietic stem cell transplant or solid organ transplant.&#xD;
&#xD;
          -  Previous malignancy and lymphoproliferative disorders (within the last 5 years) with&#xD;
             the exception of stable prostate cancer and basal cell carcinoma.&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease on long-term oxygen therapy - subjects with&#xD;
             forced expiratory volume in 1 second known to be &lt;50% will also be excluded.&#xD;
&#xD;
          -  Demyelinating disease.&#xD;
&#xD;
          -  Known history of hepatitis B, HIV, or untreated hepatitis C infection&#xD;
&#xD;
          -  Severe hepatic impairment or known cirrhosis - Child-Pugh score B or higher.&#xD;
&#xD;
          -  Acute kidney injury Stage 3&#xD;
&#xD;
          -  Tuberculosis or other severe infections such as (non-COVID-19) sepsis, abscesses,&#xD;
             fungal superinfection and opportunistic infections requiring treatment.&#xD;
&#xD;
          -  Positive Quantiferon Gold test at screening&#xD;
&#xD;
          -  Moderate or severe heart failure (New York Heart Association Class III/IV).&#xD;
&#xD;
          -  Treatment with monoclonal antibodies targeting cytokines (e.g., TNF inhibitors&#xD;
             [adalimumab, infliximab, etanercept, golimumab, certolizumab]; anti-IL-1 [e.g.,&#xD;
             anakinra, canakinumab]; anti-IL-6 or anti-IL-6r [e.g., tocilizumab, sarilumab,&#xD;
             sitlukimab]; or T-cells [e.g., abatacept]) in past 90 days (5 half-lives of the drug),&#xD;
             or contemplating treatment with any of these agents during the trial period.&#xD;
&#xD;
          -  Treatment with monoclonal antibodies targeting B-cells (e.g., rituximab, and including&#xD;
             any targeting multiple cell lines including B-cells) in the 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Received GM-CSF agents (e.g., sargramostim) within 2 months prior to screening.&#xD;
&#xD;
          -  Treatment with other immunosuppressants in the 4 weeks prior to screening and in the&#xD;
             judgment of the Investigator, the risk of immunosuppression with adalimumab is larger&#xD;
             than the risk of COVID-19.&#xD;
&#xD;
          -  Treatment with small molecule tyrosine kinase inhibitors (e.g., baricitinib,&#xD;
             ibrutinib, acalabrutinib, imatinib, gefitinib), in the 4 weeks prior to screening.&#xD;
&#xD;
          -  Received or contemplating receipt of any live vaccine or any investigational vaccine&#xD;
             in the 4 weeks prior to screening.&#xD;
&#xD;
          -  Current participation or previous participation in any other clinical trial within 30&#xD;
             days prior to randomization.&#xD;
&#xD;
          -  Subjects with known hypersensitivity to adalimumab or excipients of adalimumab as&#xD;
             stated in the label.&#xD;
&#xD;
          -  Pregnant female&#xD;
&#xD;
          -  Lactating female&#xD;
&#xD;
          -  Women of childbearing potential who do not agree to either abstinence or use of at&#xD;
             least one primary form of contraception (not including hormonal contraception) from&#xD;
             the time of screening through Day 29 following randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 10, 2021</study_first_submitted>
  <study_first_submitted_qc>January 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 10, 2021</last_update_submitted>
  <last_update_submitted_qc>January 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

